Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
In millions, except per share items | Sep-24-22 | Sep-25-21 | Sep-26-20 | Sep-28-19 | Sep-29-18 | Sep-30-17 | Sep-24-16 | Sep-26-15 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Revenues: |
Breast Health | 1,227.8 | 1,352.3 | 1,151.9 | 1,314.2 | 1,218.2 | 1,138.3 | 1,112.8 | 1,063.4 |
Diagnostics | 3,018.5 | 3,695.0 | 2,102.1 | 1,205.5 | 1,147.4 | 1,197.1 | 1,236.9 | 1,211.8 |
GYN Surgical | 522.9 | 488.1 | 376.1 | 437.2 | 422.0 | 427.1 | 393.1 | 335.8 |
Skeletal Health | 93.6 | 96.9 | 81.0 | 94.8 | 91.2 | 88.8 | 89.9 | 94.0 |
Other | | | 65.3 | 315.6 | 339.1 | 207.5 | | |
Total revenues [+] | 4,862.8 | 5,632.3 | 3,776.4 | 3,367.3 | 3,217.9 | 3,058.8 | 2,832.7 | 2,705.0 |
Products | | | | | | | 2,379.0 | 2,270.4 |
Services | | | | | | | 453.7 | 434.6 |
Revenue growth [+] | -13.7% | 49.1% | 12.1% | 4.6% | 5.2% | 8.0% | 4.7% | 6.9% |
Breast Health | -9.2% | 17.4% | -12.3% | 7.9% | 7.0% | 2.3% | 4.6% | 12.6% |
Diagnostics | -18.3% | 75.8% | 74.4% | 5.1% | -4.2% | -3.2% | 2.1% | 2.1% |
GYN Surgical | 7.1% | 29.8% | -14.0% | 3.6% | -1.2% | 8.6% | 17.1% | 9.1% |
Skeletal Health | -3.4% | 19.6% | -14.6% | 3.9% | 2.7% | -1.2% | -4.4% | 3.0% |
Cost of goods sold [+] | 295.7 | 276.7 | 253.2 | 318.5 | 319.4 | 62.5 | 1,065.7 | 1,272.3 |
Cost of product sales | | | | | | | 756.8 | 755.5 |
Cost of services | | | | | | | 219.2 | 217.1 |
Amortization of intangibles | | | | | | | 89.7 | 299.7 |
Gross profit | 4,567.1 | 5,355.6 | 3,523.2 | 3,048.8 | 2,898.5 | 2,996.3 | 1,767.0 | 1,432.7 |
Gross margin | 93.9% | 95.1% | 93.3% | 90.5% | 90.1% | 98.0% | 62.4% | 53.0% |
Selling, general and administrative [+] | 1,038.0 | 994.4 | 840.3 | 897.2 | 910.7 | 841.9 | 682.4 | 624.0 |
Sales and marketing | 630.3 | 561.2 | 484.6 | 564.9 | 544.6 | 498.6 | 415.1 | 363.0 |
General and administrative | 407.7 | 433.2 | 355.7 | 332.3 | 366.1 | 343.3 | 267.3 | 261.0 |
Research and development | 283.4 | 276.3 | 222.5 | 232.2 | 218.7 | 232.8 | 232.1 | 214.9 |
Other operating expenses | 1,614.9 | 1,602.0 | 1,335.4 | 1,351.2 | 1,261.1 | 2,337.5 | 293.4 | 110.2 |
EBITDA [+] | 2,060.9 | 2,889.8 | 1,501.0 | 1,031.3 | 988.3 | 33.3 | 1,024.5 | 975.0 |
EBITDA growth | -28.7% | 92.5% | 45.5% | 4.4% | 2867.9% | -96.7% | 5.1% | 9.9% |
EBITDA margin | 42.4% | 51.3% | 39.7% | 30.6% | 30.7% | 1.1% | 36.2% | 36.0% |
Depreciation | 89.2 | 88.0 | 83.1 | 92.5 | 101.6 | 89.6 | 82.3 | 81.5 |
EBITA | 1,971.7 | 2,801.8 | 1,417.9 | 938.8 | 886.7 | -56.3 | 942.2 | 893.5 |
EBITA margin | 40.5% | 49.7% | 37.5% | 27.9% | 27.6% | -1.8% | 33.3% | 33.0% |
Amortization of intangibles | 340.9 | 318.9 | 292.9 | 370.6 | 378.7 | 359.6 | 383.1 | 409.9 |
EBIT [+] | 1,630.8 | 2,482.9 | 1,125.0 | 568.2 | 508.0 | -415.9 | 559.1 | 483.6 |
EBIT growth | -34.3% | 120.7% | 98.0% | 11.9% | -222.1% | -174.4% | 15.6% | 33.0% |
EBIT margin | 33.5% | 44.1% | 29.8% | 16.9% | 15.8% | -13.6% | 19.7% | 17.9% |
Non-recurring items [+] | -9.4 | 2.6 | 20.0 | 692.0 | 745.9 | -1,786.1 | 10.5 | 28.5 |
Asset impairment | 27.7 | | 4.4 | 685.4 | 731.7 | | | |
Loss (gain) on sale of assets | | | | | | -899.7 | | |
Loss (gain) on sale of business | | | | | | -899.7 | | |
Interest expense, net [+] | 82.2 | 92.2 | 112.2 | 136.2 | 142.4 | 149.4 | 154.6 | 204.2 |
Interest expense | 95.1 | 93.6 | 116.5 | 140.8 | 148.7 | 153.2 | 155.3 | 205.5 |
Interest income | 12.9 | 1.4 | 4.3 | 4.6 | 6.3 | 3.8 | 0.7 | 1.3 |
Other income (expense), net [+] | 30.2 | -27.0 | 9.1 | 2.3 | -38.3 | 9.7 | 21.3 | -73.7 |
Gain (loss) on debt retirement | -0.7 | -21.6 | | -0.8 | -45.9 | -3.2 | -5.3 | -62.7 |
Other | 30.9 | -5.4 | 9.1 | 3.1 | 7.6 | 12.9 | 26.6 | -11.0 |
Pre-tax income | 1,588.2 | 2,361.1 | 1,001.9 | -257.7 | -418.6 | 1,230.5 | 415.3 | 177.2 |
Income taxes | 286.2 | 491.4 | -108.6 | -54.1 | -307.3 | 475.0 | 84.5 | 45.6 |
Tax rate | 18.0% | 20.8% | | 21.0% | 73.4% | 38.6% | 20.3% | 25.7% |
Net income | 1,302.0 | 1,869.7 | 1,110.5 | -203.6 | -111.3 | 755.5 | 330.8 | 131.6 |
Net margin | 26.8% | 33.2% | 29.4% | -6.0% | -3.5% | 24.7% | 11.7% | 4.9% |
|
Basic EPS [+] | $5.18 | $7.27 | $4.23 | ($0.76) | ($0.40) | $2.70 | $1.18 | $0.47 |
Growth | -28.8% | 72.1% | -659.3% | 86.8% | -115.0% | 128.7% | 151.7% | 647.0% |
Diluted EPS [+] | $5.13 | $7.20 | $4.20 | ($0.76) | ($0.40) | $2.64 | $1.16 | $0.45 |
Growth | -28.8% | 71.5% | -655.3% | 86.8% | -115.3% | 128.8% | 154.3% | 631.3% |
|
|
Shares outstanding (basic) [+] | 251.5 | 257.0 | 262.7 | 269.4 | 275.1 | 279.8 | 280.2 | 280.6 |
Growth | -2.1% | -2.2% | -2.5% | -2.1% | -1.7% | -0.1% | -0.1% | 1.8% |
Shares outstanding (diluted) [+] | 253.8 | 259.7 | 264.6 | 269.4 | 275.1 | 285.7 | 286.2 | 289.5 |
Growth | -2.3% | -1.9% | -1.8% | -2.1% | -3.7% | -0.2% | -1.2% | 4.0% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|